Literature DB >> 2882787

Neuroleptic-induced parkinsonism in older schizophrenics.

W F Hoffman, S M Labs, D E Casey.   

Abstract

The association of neuroleptic drug-induced parkinsonism (DIP) with factors related to brain structure and function are poorly understood. Twenty-one medicated schizophrenics over age 55 years were evaluated for parkinsonism, tardive dyskinesia, psychiatric symptoms, ventricular/brain ratio (VBR), and neuropsychological function. Sixteen (76%) of the patients had DIP, whereas 10 (48%) had tardive dyskinesia. Increased severity of parkinsonism was significantly associated with larger VBR and the severity of negative symptoms. Severity of parkinsonism predicted poor visual-spatial function, whereas negative symptoms were modestly predictive of impairment in both verbal ability and cognitive flexibility. These findings suggest that brain atrophy may be a risk factor for DIP. The pattern of cognitive dysfunction associated with DIP in this sample is similar to that found in idiopathic Parkinson's disease. Dopaminergic dysfunction may underlie the pattern of pathology described in this report.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2882787     DOI: 10.1016/0006-3223(87)90165-x

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  8 in total

Review 1.  Effect of neuroleptics on positive and negative symptoms and the deficit state.

Authors:  J Angst; H H Stassen; B Woggon
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 2.  Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations.

Authors:  M R Caligiuri; D V Jeste; J P Lacro
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 3.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

4.  A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.

Authors:  H J Möller; H Müller; R L Borison; N R Schooler; G Chouinard
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

Review 5.  Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Authors:  Prakash S Masand; Sanjay Gupta
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 6.  Management of the negative symptoms of schizophrenia: new treatment options.

Authors:  Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 7.  Tardive dyskinesia.

Authors:  D E Casey
Journal:  West J Med       Date:  1990-11

Review 8.  Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review.

Authors:  Sharadha Wisidagama; Abiram Selladurai; Peter Wu; Marco Isetta; Jordi Serra-Mestres
Journal:  Medicines (Basel)       Date:  2021-05-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.